Our Pipeline

Advanced Pipeline, Aggressive Timeline

At Anji, we focus on high-value, innovative projects that have been credentialed by human data. With a lean operational model that avoids bureaucracy and red tape, we can pursue the best ideas at the right time and work quickly and efficiently to help patients across the globe.

We Focus on What Works

Our custom-built portfolio prioritizes unmet need, without limitations on disease area or therapeutic modality.

Metabolic Disease Pipeline

Molecule
ANJ900 MetDR
Pre-clinical
Phase 1
Phase 2
Phase 3
ANJ908 Pradigastat
ANJ028 ApoE Mimetic

Oncology Pipeline

Molecule
ANJ810 MCL 1 inhibitor
Pre-clinical
Phase 1
Phase 2
Phase 3
Anji’s oncology programs are being developed by its subsidiary, Anji Onco, Inc.

For partnerships, investment opportunities, or to learn more about our work, contact us.